Gamble Program for Clinical Studies

  • Research Emphasis

    Areas of research emphasis include:

    • Herpes viral diseases (genital herpes, cold sores, congenital CMV)
    • Respiratory diseases (influenza, respiratory syncytial virus, common cold, pneumococcal pneumonia)
    • Diarrheal diseases (rotavirus, norovirus, bacterial)
    • Microbicides
    • Sexually transmitted diseases (HPV)
    • Infections in international adoptees

    Vaccine research has included clinical evaluations in all age groups (infants to elderly). Specific vaccines include:

    • Influenza
    • Cytomegalovirus (CMV) (inactivated and live-attenuated)
    • Herpes type 1 and 2 (HSV)
    • Rotavirus
    • Acellular pertussis
    • Meningococcal
    • Pneumococcal
    • Respiratory syncytial virus (RSV)
    • Parainfluenza
    • Parvovirus
    • Cholera
    • Norovirus
    • Salmonella
    • Human papillomavirus (HPV)
    • New combinations of childhood vaccines

    Highlights

    The highlight of the Gamble Program was the licensure of the rotavirus vaccine developed by Gamble investigators Richard Ward and David Bernstein.  The vaccine licensed to GlaxoSmithKline and sold as Rotarix is available in more than 100 countries including the United States and Europe.

    Antiviral drug research has included evaluation of agents for:

    • Influenza
    • Rhinovirus
    • Genital herpes
    • Herpes labialis
    • Enteroviruses

    These studies have involved natural and experimental viral challenges.

    Over the years, the Gamble Program has been well funded. Current funding includes an NIH VTEU (Vaccine Treatment and Evaluation Unit) contract, an NIH antiviral contract and numerous industrial sponsors.